## **Open Board Meeting**

## Thursday, April 25, 2024 Teleconference

## **AGENDA**

	5	1.	Open Board Meeting	Chair Silver
			Welcome & Land Acknowledgement	
		2.	Declaration of Conflict of Interest	Chair Silver
		3.	Open Consent Agenda	Chair Silver
			a) Items for Further Discussion	
			b) Approval of Open Consent Items [DECISION]	
		4.	Confirmation of Open Agenda [DECISION]	Chair Silver
8:35am - 9:10am	35	5.	Governance Committee:	Anne Peterson
			a) New Board Member Onboarding Requirement	Chair, Governance Committe
			i) Board Reference and Policies Revisions [DECISION]	
			ii) New Board Members Signing of Declaration	
			b) Board Code of Conduct Revisions [DECISION]	
9:10am - 9:40am	30	6.	Strategic Plan:	Andrea Silver
			Goal 1: Continuous Quality Improvement	Chair, Legislation Review Committee
			a) Expectations of Care Poster	Committee
			a) Expectations of Care - Poster  Develop expectation of pharmacy care that increases the	
			transparency and awareness of what the public can expect from pharmacy professionals	
			i) Drawcood Amendments to DODGA Dulawa section 22.4 and Filing with	
			<ul> <li>i) Proposed Amendments to PODSA Bylaws section 23.4 and Filing with the Ministry of Health [DECISION]</li> </ul>	
			ii) Proposed New PPP-77: Signage within the Pharmacy, and approval for	
			effective date [DECISION]	
			BREAK	
9:40am - 9:55am	15			
		7.	Strategic Plan:	
	15 60	7.	Strategic Plan:  Goal 1: Continuous Quality Improvement	Carolyn Hoffman
		7.	Strategic Plan: Goal 1: Continuous Quality Improvement	Carolyn Hoffman CEO, ISMP Canada
9:40am - 9:55am 9:55am - 10:55am		7.	Goal 1: Continuous Quality Improvement	CEO, ISMP Canada
		7.	<u>Goal 1: Continuous Quality Improvement</u> b) Medication Incident Reporting (MIR)	CEO, ISMP Canada Sylvia Hyland
		7.	b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a
		7.	b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a Privacy Officer, ISMP Canad
		7.	b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a Privacy Officer, ISMP Canad Melissa Sheldrick
		7.	b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a Privacy Officer, ISMP Canad Melissa Sheldrick Patient and Family Advisor
		7.	Goal 1: Continuous Quality Improvement  b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes  Presentation:	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a Privacy Officer, ISMP Canad Melissa Sheldrick Patient and Family Advisor ISMP Canada
		7.	b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes	CEO, ISMP Canada Sylvia Hyland Vice President, Operations at Privacy Officer, ISMP Canad Melissa Sheldrick Patient and Family Advisor, ISMP Canada Enna Aujla
		7.	Goal 1: Continuous Quality Improvement  b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes  Presentation:	CEO, ISMP Canada Sylvia Hyland Vice President, Operations ar Privacy Officer, ISMP Canad Melissa Sheldrick Patient and Family Advisor, ISMP Canada Enna Aujla Director, Community Pharma
		7.	Goal 1: Continuous Quality Improvement  b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes  Presentation:	CEO, ISMP Canada Sylvia Hyland Vice President, Operations an Privacy Officer, ISMP Canad Melissa Sheldrick Patient and Family Advisor, ISMP Canada Enna Aujla
		7.	Goal 1: Continuous Quality Improvement  b) Medication Incident Reporting (MIR)  Develop and implement MIR to identify trends in incidents across the province and to identify opportunities to learn and improve practice and health outcomes  Presentation:	CEO, ISMP Canada Sylvia Hyland Vice President, Operations a Privacy Officer, ISMP Canada Melissa Sheldrick Patient and Family Advisor ISMP Canada Enna Aujla Director, Community Pharma Reporting and Learning, ISM